With another earnings season upon us, the Fool's health-care team is busy making sure investors know what to expect from their favorite companies this quarter, while also maintaining a focus on the long term.
In the following video, health-care bureau chief Brenton Flynn outlines some derivative insights from today's Johnson & Johnson (JNJ +1.31%) earnings call, where he made a number of observations and found implications for Medivation (MDVN +0.00%), Zimmer (NYSE: ZMH), Stryker (SYK 0.17%), and potentially Abbott Labs (ABT +0.19%).